Navigation Links
ACEA Presents xCELLigence Research Grant to Dr. Teresa Krabbe
Date:3/1/2019

Teresa Krabbe, Ph.D., a student in the working group of Dr. Jennifer Altomonte at Klinikum Rechts der Isar of the Technical University Munich, has been awarded an xCELLigence Research Grant for her proposal to develop adoptive T cell therapy as a complimentary immunotherapeutic for an improved oncolytic virus platform.

Oncolytic viruses represent an exciting new aspect in the evolving field of cancer immunotherapy. Dr. Krabbe and colleagues have previously engineered a novel hybrid vector comprising vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV), named rVSV-NDV. This recombinant virus can induce tumor-specific syncytia formation, allowing for efficient cell-to-cell spread of the virus and rapid onset of immunogenic cell death. Furthermore, the toxicity associated with the wildtype VSV has been abrogated through this engineering approach.

Nevertheless, as with all oncolytic viruses, the relative inefficiency of systemic delivery of the vector remains a major challenge. To address this issue, Krabbe hypothesized that adoptively transferred T cell receptor transgenic T (TCR-T) cells could be used as cell carriers to deliver the rVSV-NDV viruses and to provide synergistic effector functions. To generate preliminary data to support her hypothesis, she will employ in vitro studies which will be facilitated by the xCELLigence RTCA system.

The goals of this study include 1) the characterization of the fusogenic oncolytic rVSV-NDV by impedance monitoring, and 2) the evaluation of an innovative strategy combining VSV-NDV with TCR-T as a delivery vehicle for the virus or using the virus to prime the tumor cells for a more effective T cell therapy. With the xCELLigence RTCA platform, Dr. Krabbe will be able to illustrate the synergistic effect in vitro in real-time.

“I am thrilled about the opportunity to work with the xCELLigence to continuously monitor tumor cells infected with our fusogenic oncolytic virus. It will greatly improve our ability to track the morphological changes that occur at very early stages of infection,” stated Dr. Krabbe. “We are working on a combination of our oncolytic virus platform with TCR-T cells and hope to illustrate a synergistic effect in vitro by real time cell analysis with the xCELLigence.”

“In September 2018, we awarded the first xCELLigence Immunotherapy Research grant to a young postdoctoral fellow at Massachusetts General Cancer Center for CAR-T research. We are excited to see Real Time Cell Analysis technology to be applied with the transgenic T Cell receptors in an oncolytic virus platform,” stated Dr. Yama Abassi, Vice President of ACEA Biosciences. “ We are expecting great data from this study, resulting in further collaboration between the Technical University of Munich and ACEA Bioscience.”

ACEA Biosciences is now accepting applications for the next xCELLigence Research Grant funding period, which is open to all cell analysis applications. For six months, the research grant winner will be provided access to the xCELLigence RTCA DP instrument, consumables, and consultation. Click here to apply.

About xCELLigence® Real Time Cell Analysis (RTCA)

ACEA Biosciences’ xCELLigence RTCA instruments are being used in both academia and industry for life science applications ranging from cancer immunotherapy, bacterial biofilms, vaccine development and cardiotoxicity testing. With the xCELLigence technology, scientists can non-invasively monitor the behavior of cells by quantifying cell proliferation, morphology change, and attachment quality in a label-free, real-time manner.

About ACEA Biosciences, A Part of Agilent Technologies

ACEA Biosciences, a part of Agilent Technologies, is a pioneer in the development and commercialization of high-performance cell analysis platforms for life science research. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® Quanteon flow cytometers are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 3,000 instruments have been placed globally, and have been used in more than 2,000 peer-reviewed publications. For more information visit: http://www.aceabio.com. Follow on LinkedIn, Twitter, and Facebook.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Based on more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 14,800 people worldwide. Information about Agilent is available at http://www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contact:
ACEA Biosciences, Inc.
Dr. Jeff Xue
Phone: 858-299-8023
email: jxue(at)aceabio(dot)com

Read the full story at https://www.prweb.com/releases/acea_presents_xcelligence_research_grant_to_dr_teresa_krabbe/prweb16138686.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Rigaku Presents Latest XRM and CT Technology at 2019 TSM Meeting
2. Ambry Genetics Presents Research on the Importance of Reclassifying Disease-Causing Genes at the National Society of Genetic Counselors (NSGC) Annual Meeting
3. Horizon Discovery Presents an Educational Webinar on CRISPR-Cas9 Genome Engineering in Primary T cells
4. The 5th Annual Mobile in Clinical Trials Event Presents Agenda for September 24, 2018
5. DERMALOG Presents the Worlds First Combined Fingerprint and Passport Scanner
6. Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020
7. NXT-ID, Inc.s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC.
8. DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015
9. Field Museum presents conservation award to founder of popular environmental website
10. Louisiana Tech University professor presents at International Bioprinting Congress
11. BGI presents a high-quality gene catalog of human gut microbiome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... WENDELSHEIM, De. and OAKLAND, Calif. (PRWEB) , ... ... ... of autoimmune, allergy, food intolerance, and infectious disease diagnostics and automation – is ... website is an online quality control resource giving customers access to lot-specific information, ...
(Date:3/9/2019)... , ... March 08, 2019 , ... ... is pleased to announce a new initiative focused on women in the field. ... day, free program that seeks to celebrate and empower emerging female leaders in ...
(Date:3/1/2019)... ... March 01, 2019 , ... Geneious would like to ... easy alternative to Vector NTI. , Geneious Prime already has a dedicated ... from Vector NTI, so that files will be organised in Geneious in the same ...
Breaking Biology News(10 mins):
(Date:3/11/2019)... , ... March 11, 2019 , ... In this live ... to improve your clinical trial efficiency and experience. Participants will learn how to use ... IRT expertise to ensure that the simple or complex randomization scheme is properly designed ...
(Date:3/5/2019)... ... 05, 2019 , ... San Fransisko, or Sisko for short, is a German ... old to pursue a career in dressage. According to Deborah, dressage came easy ... she’d ever worked with. Unfortunately, Sisko suffered an injury while playing in his ...
(Date:2/27/2019)... ... February 26, 2019 , ... ... industrial automation and IT solutions with 140 employees on both the east and ... engineer’s license in the State of New Hampshire. Sandmaier, a senior project engineer, ...
(Date:2/22/2019)... ... February 20, 2019 , ... Ocean Tomo ... Systems. , The patents in lot 92 relate to ... used to distinguish between human users and computers through exploiting the fundamental differences ...
Breaking Biology Technology: